Pharma Company Patent Estate Rankings
190
Companies tracked
8,695
Active US patents
$NaNM
5-yr revenue at risk
72
AI strategic briefs
Free tier: first 25 rows · Upgrade to Pro for full 190-row export.
| # | Company | Active patents | Avg vuln | Ironclad | Vulnerable | 5-yr at risk | First major cliff |
|---|---|---|---|---|---|---|---|
| 1 |
AbbVie Inc.
Brief
12 drugs · 726 patents tracked
|
726 | 46 | 130 | 83 | $553.7B | 2026 (—) |
| 2 |
Pfizer Inc. (originally Searle/Pharmacia)
Brief
43 drugs · 671 patents tracked
|
650 | 52 | 125 | 177 | $28.3B | 2026 (—) |
| 3 |
Boehringer Ingelheim
Brief
7 drugs · 623 patents tracked
|
610 | 61 | 33 | 168 | $1087.5B | 2026 (—) |
| 4 |
Vertex Pharms Inc
Brief
2 drugs · 426 patents tracked
|
426 | 50 | 40 | 16 | — | — |
| 5 |
Johnson & Johnson (Janssen)
Brief
10 drugs · 415 patents tracked
|
415 | 60 | 14 | 137 | $91.9B | 2027 (+1yr) |
| 6 |
AstraZeneca K.K.
Brief
12 drugs · 404 patents tracked
|
374 | 63 | 31 | 142 | $969.5B | 2026 (—) |
| 7 |
Teva Pharms Intl
Brief
3 drugs · 373 patents tracked
|
371 | 61 | 11 | 92 | $13.3B | 2031 (+5yr) |
| 8 |
Generic (originally Yamanouchi/Merck)
Brief
18 drugs · 380 patents tracked
|
370 | 60 | 2 | 89 | $447.0B | 2026 (—) |
| 9 |
Eli Lilly
Brief
6 drugs · 353 patents tracked
|
353 | 62 | 43 | 196 | $2.4B | 2029 (+3yr) |
| 10 |
Novo Nordisk
Brief
2 drugs · 225 patents tracked
|
182 | 44 | 23 | 0 | $767.2B | 2026 (—) |
| 11 |
Merck & Co.
16 drugs · 172 patents tracked
|
162 | 57 | 11 | 37 | $5.9B | 2029 (+3yr) |
| 12 |
Aton
1 drugs · 151 patents tracked
|
151 | 53 | 0 | 0 | — | — |
| 13 |
Gilead Sciences
Brief
5 drugs · 143 patents tracked
|
143 | 47 | 21 | 16 | $26.4B | 2029 (+3yr) |
| 14 |
Fresenius Kabi
Brief
4 drugs · 141 patents tracked
|
138 | 51 | 0 | 17 | — | — |
| 15 |
Roche Palo
Brief
8 drugs · 123 patents tracked
|
123 | 47 | 37 | 35 | $3.5B | 2033 (+7yr) |
| 16 |
Amarin Pharms
1 drugs · 122 patents tracked
|
122 | 50 | 0 | 0 | — | — |
| 17 |
Novartis AG (originally Sandoz)
Brief
13 drugs · 135 patents tracked
|
120 | 53 | 30 | 48 | $16.7B | 2027 (+1yr) |
| 18 |
Ipsen
Brief
3 drugs · 117 patents tracked
|
117 | 59 | 8 | 53 | — | — |
| 19 |
Innocoll
Brief
1 drugs · 108 patents tracked
|
108 | 64 | 0 | 49 | — | — |
| 20 |
Bausch Health
Brief
9 drugs · 108 patents tracked
|
97 | 56 | 5 | 31 | $25.5B | 2027 (+1yr) |
| 21 |
Indivior
Brief
1 drugs · 96 patents tracked
|
96 | 62 | 0 | 39 | $35.2B | 2027 (+1yr) |
| 22 |
United Therap
1 drugs · 80 patents tracked
|
80 | 54 | 10 | 37 | $138.0B | 2027 (+1yr) |
| 23 |
Purdue Pharma Lp
Brief
1 drugs · 79 patents tracked
|
79 | 71 | 0 | 51 | $11.2B | 2026 (—) |
| 24 |
GSK (originally Glaxo)
Brief
7 drugs · 78 patents tracked
|
72 | 63 | 6 | 40 | $10.5B | 2027 (+1yr) |
| 25 |
Alkermes Inc
Brief
1 drugs · 71 patents tracked
|
71 | 44 | 5 | 0 | $7.5B | — |
| 26 |
Arcutis
Brief
1 drugs · 68 patents tracked
|
68 | 62 | 0 | 26 | — | — |
| 27 |
Bristol-Myers Squibb
Brief
9 drugs · 67 patents tracked
|
67 | 60 | 8 | 28 | $228.6B | 2026 (—) |
| 28 |
Amgen
Brief
4 drugs · 69 patents tracked
|
66 | 55 | 9 | 25 | $38.1B | 2026 (—) |
| 29 |
Vero Biotech Inc
1 drugs · 67 patents tracked
|
66 | 67 | 0 | 22 | — | — |
| 30 |
Otsuka
Brief
3 drugs · 88 patents tracked
|
64 | 55 | 18 | 25 | $69.6B | 2026 (—) |
| 31 |
Vanda Pharmaceuticals
Brief
1 drugs · 63 patents tracked
|
63 | 81 | 0 | 63 | — | — |
| 32 |
Marius
1 drugs · 64 patents tracked
|
61 | 65 | 6 | 39 | — | — |
| 33 |
Vanda Pharms Inc
1 drugs · 56 patents tracked
|
56 | 69 | 0 | 7 | — | — |
| 34 |
Astellas Pharma
Brief
3 drugs · 51 patents tracked
|
48 | 66 | 4 | 30 | $75.0B | 2026 (—) |
| 35 |
Biogen Us
Brief
5 drugs · 46 patents tracked
|
46 | 53 | 11 | 17 | $7.1B | 2028 (+2yr) |
| 36 |
Takeda
Brief
5 drugs · 58 patents tracked
|
45 | 61 | 5 | 18 | $6.0B | — |
| 37 |
Baxter
Brief
4 drugs · 45 patents tracked
|
45 | 56 | 1 | 8 | — | 2035 (+9yr) |
| 38 |
Handa Therap
1 drugs · 48 patents tracked
|
42 | 61 | 6 | 30 | $3.0B | — |
| 39 |
Exeltis Usa Inc
1 drugs · 42 patents tracked
|
42 | 64 | 0 | 16 | — | — |
| 40 |
Scilex Pharms
1 drugs · 41 patents tracked
|
41 | 72 | 0 | 32 | — | — |
| 41 |
Haleon Us Holdings
Brief
1 drugs · 42 patents tracked
|
41 | 61 | 2 | 9 | $127.1B | 2027 (+1yr) |
| 42 |
Ucb Inc
Brief
4 drugs · 47 patents tracked
|
40 | 61 | 0 | 17 | $2.0B | — |
| 43 |
Purdue Pharma
1 drugs · 40 patents tracked
|
40 | 51 | 0 | 0 | — | — |
| 44 |
Bayer AG
Brief
5 drugs · 39 patents tracked
|
39 | 43 | 11 | 11 | $4.8B | 2030 (+4yr) |
| 45 |
Mayne Pharma
Brief
1 drugs · 38 patents tracked
|
38 | 70 | 0 | 22 | — | — |
| 46 |
Sanofi
Brief
5 drugs · 38 patents tracked
|
38 | 62 | 0 | 6 | $8.8B | 2026 (—) |
| 47 |
Besins Hlthcare
1 drugs · 38 patents tracked
|
38 | 72 | 0 | 16 | — | — |
| 48 |
Jan Beumer
Brief
1 drugs · 36 patents tracked
|
36 | 69 | 3 | 21 | — | — |
| 49 |
Azurity
Brief
4 drugs · 36 patents tracked
|
34 | 47 | 0 | 8 | — | — |
| 50 |
Global Blood Theraps
1 drugs · 32 patents tracked
|
32 | 27 | 12 | 0 | — | — |
| 51 |
Acadia Pharms Inc
Brief
1 drugs · 32 patents tracked
|
32 | 62 | 4 | 12 | — | — |
| 52 |
Jazz Pharms Res
1 drugs · 32 patents tracked
|
32 | 48 | 0 | 0 | — | 2035 (+9yr) |
| 53 |
Deciphera Pharms
1 drugs · 30 patents tracked
|
30 | 57 | 6 | 15 | — | — |
| 54 |
Blueprint Medicines
1 drugs · 29 patents tracked
|
29 | 58 | 5 | 9 | — | — |
| 55 |
Insmed Inc
1 drugs · 28 patents tracked
|
28 | 68 | 2 | 22 | — | — |
| 56 |
Ascendis Pharma Bone
1 drugs · 27 patents tracked
|
27 | 61 | 6 | 18 | — | — |
| 57 |
BeiGene
Brief
1 drugs · 25 patents tracked
|
25 | 62 | 4 | 17 | — | — |
| 58 |
Kai Pharms Inc
1 drugs · 24 patents tracked
|
24 | 45 | 6 | 3 | — | — |
| 59 |
Chiesi
Brief
3 drugs · 24 patents tracked
|
24 | 44 | 0 | 2 | $400M | — |
| 60 |
Accord Hlthcare
Brief
2 drugs · 25 patents tracked
|
24 | 54 | 1 | 2 | $2.7B | — |
| 61 |
Am Regent
Brief
1 drugs · 24 patents tracked
|
24 | 75 | 2 | 20 | — | — |
| 62 |
Apgdi
1 drugs · 22 patents tracked
|
22 | 53 | 0 | 0 | $36.0B | 2028 (+2yr) |
| 63 |
Thea Pharma
1 drugs · 20 patents tracked
|
20 | 65 | 1 | 9 | — | — |
| 64 |
Servier
Brief
2 drugs · 20 patents tracked
|
20 | 57 | 4 | 8 | — | — |
| 65 |
Rigel Pharms
2 drugs · 20 patents tracked
|
20 | 52 | 3 | 7 | — | — |
| 66 |
Sumitomo Pharma Am
Brief
1 drugs · 28 patents tracked
|
20 | 50 | 4 | 4 | — | — |
| 67 |
Kaken Pharmaceutical
Brief
1 drugs · 20 patents tracked
|
20 | 68 | 2 | 17 | — | — |
| 68 |
Cubist Pharms Llc
1 drugs · 18 patents tracked
|
18 | 63 | 3 | 12 | $6.6B | — |
| 69 |
Senju Pharmaceutical Co., Ltd
Brief
1 drugs · 18 patents tracked
|
18 | 69 | 0 | 10 | — | — |
| 70 |
National Cancer Institute (NCI)
1 drugs · 18 patents tracked
|
18 | 64 | 0 | 6 | — | — |
| 71 |
Corcept Therap
1 drugs · 18 patents tracked
|
18 | 47 | 0 | 0 | — | — |
| 72 |
Hisamitsu
1 drugs · 18 patents tracked
|
18 | 33 | 0 | 0 | — | — |
| 73 |
Yonsei University
1 drugs · 18 patents tracked
|
18 | 53 | 0 | 1 | — | — |
| 74 |
Sarepta
Brief
3 drugs · 16 patents tracked
|
16 | 58 | 2 | 3 | $3.6B | — |
| 75 |
Acacia
Brief
1 drugs · 16 patents tracked
|
16 | 70 | 0 | 11 | — | — |
| 76 |
Casper Pharma Llc
1 drugs · 16 patents tracked
|
16 | 63 | 2 | 6 | — | — |
| 77 |
Neurocrine
Brief
1 drugs · 16 patents tracked
|
16 | 75 | 0 | 16 | — | — |
| 78 |
Horizon Therap Us
1 drugs · 15 patents tracked
|
15 | 52 | 0 | 0 | — | — |
| 79 |
Pharmacosmos
1 drugs · 15 patents tracked
|
15 | 43 | 3 | 3 | — | — |
| 80 |
Esperion Theraps Inc
1 drugs · 15 patents tracked
|
15 | 46 | 6 | 6 | — | — |
| 81 |
Incyte Corp
Brief
1 drugs · 15 patents tracked
|
15 | 45 | 6 | 6 | — | — |
| 82 |
Trevena
Brief
1 drugs · 15 patents tracked
|
15 | 71 | 0 | 3 | — | — |
| 83 |
Nippon Shinyaku Co., Ltd.
Brief
1 drugs · 15 patents tracked
|
15 | 51 | 0 | 0 | — | — |
| 84 |
Hisamitsu Pharmaceutical Co., Inc
Brief
1 drugs · 14 patents tracked
|
14 | 57 | 0 | 0 | — | — |
| 85 |
Seagen
1 drugs · 14 patents tracked
|
14 | 63 | 2 | 10 | $1.9B | — |
| 86 |
Catalyst Pharms
2 drugs · 14 patents tracked
|
14 | 44 | 2 | 5 | $2.1B | — |
| 87 |
Intercept Pharms Inc
1 drugs · 14 patents tracked
|
14 | 24 | 4 | 0 | — | — |
| 88 |
Galderma Labs Lp
1 drugs · 14 patents tracked
|
14 | 75 | 0 | 12 | — | — |
| 89 |
Paratek Pharms
1 drugs · 13 patents tracked
|
13 | 61 | 1 | 4 | — | — |
| 90 |
Sebela Womens Hlth
1 drugs · 13 patents tracked
|
13 | 43 | 0 | 0 | — | — |
| 91 |
Alnylam Pharmaceuticals
Brief
1 drugs · 13 patents tracked
|
13 | 64 | 0 | 2 | $7.7B | 2027 (+1yr) |
| 92 |
Us Army
1 drugs · 13 patents tracked
|
13 | 62 | 1 | 7 | — | — |
| 93 |
Xeris
Brief
1 drugs · 12 patents tracked
|
12 | 65 | 0 | 6 | — | — |
| 94 |
Helsinn Hlthcare
Brief
1 drugs · 12 patents tracked
|
12 | 47 | 4 | 3 | — | — |
| 95 |
Sk Life
1 drugs · 12 patents tracked
|
12 | 37 | 6 | 6 | — | — |
| 96 |
Kyowa Kirin Co., Ltd.
Brief
1 drugs · 12 patents tracked
|
12 | 52 | 0 | 0 | — | — |
| 97 |
Fdn Consumer
1 drugs · 12 patents tracked
|
12 | 48 | 1 | 0 | — | — |
| 98 |
Secura
1 drugs · 12 patents tracked
|
12 | 47 | 4 | 4 | — | — |
| 99 |
Kk Bcj-94
1 drugs · 11 patents tracked
|
11 | 64 | 0 | 6 | — | — |
| 100 |
Salix
2 drugs · 11 patents tracked
|
11 | 32 | 2 | 0 | — | — |
| 101 |
Evofem Inc
Brief
1 drugs · 11 patents tracked
|
11 | 65 | 0 | 4 | — | — |
| 102 |
Marinus
Brief
1 drugs · 11 patents tracked
|
11 | 73 | 0 | 6 | — | — |
| 103 |
Portola Pharms Inc
1 drugs · 10 patents tracked
|
10 | 59 | 2 | 4 | — | — |
| 104 |
Hope Pharms
1 drugs · 10 patents tracked
|
10 | 55 | 3 | 5 | — | — |
| 105 |
Mylan Ireland Ltd
1 drugs · 10 patents tracked
|
10 | 47 | 4 | 4 | — | — |
| 106 |
Bristol
Brief
1 drugs · 10 patents tracked
|
10 | 47 | 4 | 4 | — | — |
| 107 |
MYOVANT SCIENCES
1 drugs · 11 patents tracked
|
10 | 47 | 4 | 4 | $421M | — |
| 108 |
Tarsus
Brief
1 drugs · 9 patents tracked
|
9 | 59 | 1 | 5 | — | — |
| 109 |
Mallinckrodt Ireland
1 drugs · 9 patents tracked
|
9 | 72 | 0 | 8 | — | — |
| 110 |
Covis
3 drugs · 9 patents tracked
|
9 | 70 | 0 | 5 | — | — |
| 111 |
Radius
Brief
1 drugs · 9 patents tracked
|
9 | 65 | 0 | 5 | — | — |
| 112 |
Sun Pharma
Brief
1 drugs · 8 patents tracked
|
8 | 72 | 0 | 5 | — | — |
| 113 |
Kura
1 drugs · 8 patents tracked
|
8 | 41 | 2 | 0 | — | — |
| 114 |
Ptc Therap
1 drugs · 8 patents tracked
|
8 | 75 | 0 | 8 | — | — |
| 115 |
Kalvista
1 drugs · 8 patents tracked
|
8 | 53 | 3 | 5 | — | — |
| 116 |
Ironwood Pharms Inc
1 drugs · 8 patents tracked
|
8 | 63 | 1 | 3 | — | — |
| 117 |
Hikma
Brief
2 drugs · 8 patents tracked
|
8 | 75 | 0 | 6 | — | — |
| 118 |
Anacor Pharms Inc
1 drugs · 8 patents tracked
|
8 | 66 | 1 | 4 | — | — |
| 119 |
Almirall
Brief
3 drugs · 8 patents tracked
|
8 | 44 | 2 | 2 | — | — |
| 120 |
Fougera Pharms
Brief
1 drugs · 8 patents tracked
|
8 | 50 | 0 | 0 | — | — |
| 121 |
Sage Therap
1 drugs · 8 patents tracked
|
8 | 55 | 0 | 0 | — | — |
| 122 |
Tetraphase Pharms
1 drugs · 8 patents tracked
|
8 | 35 | 4 | 0 | — | — |
| 123 |
Eisai
Brief
1 drugs · 8 patents tracked
|
8 | 60 | 0 | 0 | — | — |
| 124 |
Shilpa
1 drugs · 7 patents tracked
|
7 | 62 | 0 | 4 | — | — |
| 125 |
Lundbeck Pharms Llc
1 drugs · 7 patents tracked
|
7 | 73 | 0 | 7 | — | — |
| 126 |
Sebela Ireland Ltd
Brief
1 drugs · 6 patents tracked
|
6 | 55 | 0 | 1 | — | — |
| 127 |
X4 Pharms
1 drugs · 6 patents tracked
|
6 | 62 | 0 | 2 | — | — |
| 128 |
Blue Earth
1 drugs · 6 patents tracked
|
6 | 42 | 3 | 2 | — | — |
| 129 |
Idorsia
1 drugs · 6 patents tracked
|
6 | 63 | 1 | 4 | — | — |
| 130 |
Lexicon Pharms Inc
1 drugs · 6 patents tracked
|
6 | 61 | 2 | 4 | — | — |
| 131 |
Merz
Brief
1 drugs · 6 patents tracked
|
6 | 53 | 0 | 2 | — | — |
| 132 |
Theracosbio
1 drugs · 6 patents tracked
|
6 | 60 | 2 | 4 | — | — |
| 133 |
Taiho Oncology
1 drugs · 6 patents tracked
|
6 | 47 | 2 | 2 | — | — |
| 134 |
Sucampo Pharma Llc
1 drugs · 6 patents tracked
|
6 | 63 | 0 | 0 | — | — |
| 135 |
Genzyme Corp
1 drugs · 6 patents tracked
|
6 | 56 | 2 | 4 | — | — |
| 136 |
Emergent Biodefense
1 drugs · 6 patents tracked
|
6 | 51 | 1 | 0 | — | — |
| 137 |
ANI Pharmaceuticals
1 drugs · 5 patents tracked
|
5 | 39 | 0 | 0 | — | — |
| 138 |
Strongbridge
1 drugs · 9 patents tracked
|
5 | 57 | 0 | 0 | — | — |
| 139 |
Mycovia Pharms
1 drugs · 5 patents tracked
|
5 | 38 | 3 | 2 | — | — |
| 140 |
Alcon Labs Inc
Brief
1 drugs · 5 patents tracked
|
5 | 62 | 0 | 0 | — | — |
| 141 |
Verona Pharma
Brief
1 drugs · 5 patents tracked
|
5 | 64 | 0 | 2 | — | — |
| 142 |
Renew Pharms
1 drugs · 5 patents tracked
|
5 | 67 | 0 | 3 | — | — |
| 143 |
Jazz Pharmaceuticals
Brief
2 drugs · 5 patents tracked
|
5 | 70 | 0 | 3 | — | — |
| 144 |
Foldrx Pharms
2 drugs · 5 patents tracked
|
5 | 53 | 2 | 2 | $2.9B | 2026 (—) |
| 145 |
Leo Pharma As
1 drugs · 4 patents tracked
|
4 | 65 | 0 | 2 | — | — |
| 146 |
Kyowa Kirin
1 drugs · 4 patents tracked
|
4 | 65 | 0 | 2 | — | — |
| 147 |
Lavipharm
1 drugs · 4 patents tracked
|
4 | 54 | 0 | 0 | — | — |
| 148 |
Menarini Intl
1 drugs · 4 patents tracked
|
4 | 51 | 0 | 0 | — | — |
| 149 |
Fonseca Biosciences
1 drugs · 4 patents tracked
|
4 | 64 | 0 | 0 | — | — |
| 150 |
Rockwell Medical Inc
1 drugs · 4 patents tracked
|
4 | 75 | 0 | 4 | — | — |
Drug Landscape Pro
Export the full table to CSV
Free tier exports first 25 rows. Pro: unlimited CSV + JSON exports, programmatic API access on Team tier.
How the columns are calculated
- Active patents — Unique US Orange Book patents listed against the company's drugs whose expiry is after today.
- Avg vuln — Mean vulnerability score (0-100, higher = easier to invalidate or design around) across all scored patents in the estate. Computed from claim type, age U-curve, family size, and runway.
- Ironclad — Patent count with vulnerability under 25. These are pillars: composition-of-matter, broad genus claims, recent issuance with long runway.
- Vulnerable — Patent count with vulnerability over 70. These are IPR / design-around / paragraph IV targets.
- 5-yr at risk — Sum of annual revenue across drugs in the estate whose patents expire within the next five years.
- First major cliff — Earliest year a patent on a drug with >$500M annual revenue is set to expire.
Cross-link explorer
Each company in the table links to its full patent dashboard at /company/<slug>/patents — which shows the cliff calendar, classification breakdown, per-drug cards, and (for top companies) the strategic brief.